J Russell Hoverman, MD, PhD, discusses the details of the US Oncology Network implementation of a pilot program before participation in the Oncology Care Model.
Timothy Showalter, MD, discusses why brachytherapy is being used less and less for the treatment of cervical cancer and the importance of incentivizing quality care in payment policies.
Matthew Davids, MD, discusses the novel agents available for the treatment of chronic lymphocytic leukemia as well as strategies for sequencing monotherapies and administering combination regimens in this disease setting.
Journal of Clinical Pathways spoke with Natalie S Callander, MD, department of hematology and oncology, University of Wisconsin Cancer Center, about her presentation at the latest NCCN Congress on Hematologic Malignancies regarding individualized treatment for patients with relapsed or refractory multiple myeloma.
Journal of Clinical Pathways spoke with Lucio N Gordan, MD, medical director in the division of quality and informatics, Florida Cancer Specialists and Research Institute, regarding his recent report for the Community Oncology Alliance and the implications that setting has on cost of cancer for patients.
Journal of Clinical Pathways spoke with Ray Page, DO, PhD, medical oncologist and hematologist,The Center for Cancer and Blood Disorders (Fort Worth, TX) and Abby Wright, Senior Director of Reimbursement, Biodesix, regarding the importance of prognostic tests—such as Veristrat for lung cancer—in clinical pathways and in aiding achievement of quality measures in the Oncology Care Model.
Journal of Clinical Pathways spoke with Michael Kelley, MD, Director of the Veterans Affairs National Program for Medical Oncology, regarding the Precision Oncology Program, including updates in gene panel testing, clinical trial accessibility, and additional programs to improve oncology care for veterans.
Journal of Clinical Pathways spoke with Steve Miller, CMO, Express Scripts, regarding his thoughts on the recently approved gene therapy for acute lymphoblastic leukemia, the accompanying price tag of said therapy, and the challenges the health care system faces paying for gene therapies and making them accessible to patients.